MedTrace Logo

Topical Infliximab in Eyes With Penetrating Keratoplasty

NCT05180994 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-04-27

No results posted yet for this study

Summary

Penetrating keratoplasty is a cornea surgery involving several inflammatory complications, of which the most important is glaucoma. Researchers wish to determine whether it is safe to administer infliximab (an anti-inflammatory drug) eye drops after surgery, and whether this eye drop could prevent the occurrence of glaucoma.

Conditions

  • Glaucoma Following Surgery

Interventions

DRUG

Topical infliximab

Infliximab eye drops (10mg/ml) administered four (4) times per day for three (3) months.

OTHER

No topical infliximab

No treatment with infliximab.

Sponsors & Collaborators

  • Fonds de recherche en ophtalmologie de l'Université de Montréal

    collaborator OTHER

  • Maisonneuve-Rosemont Hospital

    collaborator OTHER

  • Niagara Health System

    collaborator OTHER

  • Prism Eye Institute

    collaborator OTHER

  • Ottawa Hospital Research Institute

    collaborator OTHER

  • Centre hospitalier de l'Université de Montréal (CHUM)

    lead OTHER

Principal Investigators

  • Marie-Claude Robert, MD · CHUM

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2027-03-01
Completion
2028-03-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05180994 on ClinicalTrials.gov